PC
CTOR

Periscope Capital’s Citius Oncology CTOR Stock Holding History

Periscope Capital’s Portfolio CTOR Stock Details CTOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-358,788
Closed -$3.93M – 441
2023
Q4 		$3.93M Buy
358,788
+17,538
+5% +$191K 0.66% 46
2023
Q3 		$3.68M Buy
341,250
+7,623
+2% +$81.4K 0.42% 84
2023
Q2 		$3.51M Buy
333,627
+9,127
+3% +$95.3K 0.27% 132
2023
Q1 		$3.36M Buy
+324,500
New +$3.33M 0.16% 204

Other funds holding CTOR

WRBC
W.R. Berkley Corp Greenwich, Connecticut $1.86B AUM 14.44% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return

Periscope Capital's CTOR Position: Q1 2024 in Review

Periscope Capital sold out of Citius Oncology (CTOR) in Q1 2024, closing a stake of 358,788 shares — an estimated $3.93M sold.

Periscope Capital first reported a position in CTOR in Q1 2023 and held it in 4 quarters. The position peaked at $3.93M in Q4 2023. 15 funds tracked by Wall St. Rank hold CTOR as of Q1 2024.

  • Periscope Capital reported no remaining Citius Oncology position as of Q1 2024 after selling out during the quarter.
  • Periscope Capital sold 358,788 Citius Oncology shares in Q1 2024, an estimated $3.93M.
  • Periscope Capital first reported a position in Citius Oncology in Q1 2023 and held it in 4 quarters.
  • Periscope Capital's Citius Oncology position peaked at $3.93M in Q4 2023.
  • 15 funds tracked by Wall St. Rank held Citius Oncology as of Q1 2024.

Based on Periscope Capital's 13F filing for Q1 2024, filed 13 May 2024.